Zentalis Pharmaceuticals in Collaboration Agreement With GlaxoSmithKline
April 12 2021 - 8:54AM
Dow Jones News
By Chris Wack
Zentalis Pharmaceuticals Inc. said it has entered into a
clinical collaboration agreement with GlaxoSmithKline PLC.
Zentalis said it will evaluate the combination of ZN-c3, an oral
WEE1 inhibitor product candidate, and Zejula niraparib,
GlaxoSmithKline's polymerase PARP inhibitor, in patients with
advanced epithelial ovarian cancer.
Zentalis is currently conducting clinical studies with ZN-c3
both as a monotherapy and in combination with certain standard of
care therapies.
Under the terms of the non-exclusive collaboration, Zentalis is
responsible for conducting the study, with GlaxoSmithKline
providing all required doses of niraparib. Zentalis will maintain
full ownership of ZN-c3.
Zentalis shares were up 21% to $45.21 in premarket trading.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
April 12, 2021 08:39 ET (12:39 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Zentalis Pharmaceuticals (NASDAQ:ZNTL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Zentalis Pharmaceuticals (NASDAQ:ZNTL)
Historical Stock Chart
From Sep 2023 to Sep 2024